How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer?

Julie R. Gralow; Allan Lipton; Alison T. Stopeck

doi:10.1200/JCO.2011.36.5759

How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer?

Julie R. Gralow
, Allan Lipton
, Alison T. Stopeck

Medical Oncology

University of Washington
Pennsylvania State University

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English
Pages (from-to)	3591-3592
Number of pages	2
Journal	Journal of Clinical Oncology
Volume	29
Issue number	26
DOIs	https://doi.org/10.1200/JCO.2011.36.5759
State	Published - Sep 10 2011

Access to Document

10.1200/JCO.2011.36.5759

Cite this

@article{49f6619affb747b1a3220cb6b445ebd2,

title = "How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer?",

author = "Gralow, \{Julie R.\} and Allan Lipton and Stopeck, \{Alison T.\}",

year = "2011",

month = sep,

day = "10",

doi = "10.1200/JCO.2011.36.5759",

language = "English",

volume = "29",

pages = "3591--3592",

journal = "Journal of Clinical Oncology",